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Background: Genetic variation within GSTM2-5 genes may interfere with detoxification of environmental
compounds, thereby having a detrimental effect on lung function following exposures such as tobacco smoke. We
aim to investigate the influence of variants and associated methylation in the GSTM gene cluster with changes in
lung function growth during adolescence.
Methods: Growth in forced expiratory volume (FEV1), forced vital capacity (FVC), and change in FEV1/FVC ratio
measures were obtained from children in the Isle of Wight birth cohort at ages 10 and 18. Illumina GoldenGate
assays were used to genotype 10 tagging polymorphisms from GSTM2 (rs574344 and rs12024479), GSTM3
(rs1537236, rs7483, and rs10735234), GSTM4 (rs668413, rs560018, and rs506008), and GSTM5 (rs929166 and rs11807)
genes. Diplotypes were generated in the software Phase 3.0.2. DNA methylation was measured in over 450,000 CpG
sites using the Infinium HumanMethylation450 BeadChip (Illumina 450K) in a subsample of 245 18-year olds from
the Isle of Wight birth cohort. Gender, age, in utero smoke exposure, secondhand smoke exposure (SHS), and
current smoking status were assessed via questionnaire; smoke exposures were validated with urine cotinine. We
used linear mixed models to estimate the effect of GSTM diplotypes on lung function across time and examine
interactions with tobacco smoke.
Results: 1,121 (77%) out of 1,456 children had information on lung function at ages 10 or 18. After adjustment for
false discovery rate, one diplotype in GSTM3 had a detrimental effect on changes in FEV1 (p=0.03), and another
diplotype in GSTM3 reduced FVC (p=0.02) over time. No significant interactions with smoking were identified. SHS
significantly modified the relationship between diplotypes and methylation levels in one GSTM2 CpG site; however,
this site did not predict lung function outcomes at age 18. Joint effects of GSTM loci and CpG sites located within
these loci on adolescent lung growth were detected.
Conclusions: Diplotypes within GSTM2-5 genes are associated with lung function growth across adolescence, but
do not appear to modify the effect of tobacco smoke exposures on adolescent lung growth. Interactions between
DNA methylation and diplotypes should be taken into account to gain further understanding on lung function in
adolescence.
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Pregnancy is a critical period of lung growth and develop-
ment, making the fetus susceptible to environmental expo-
sures [1]. Indeed, in utero exposure to tobacco smoke has
shown detrimental effects on lung health [1-4]. In utero to-
bacco smoke exposure may affect morphogenesis and mat-
uration of the lungs, leading to impaired lung health by
adulthood [2]. The toxic effect of tobacco smoke exposure
might be reduced through metabolizing xenobiotic prod-
ucts, thus minimizing oxidative stress, a physiological event
caused by the imbalance between reactive oxygen species
and the body’s ability to detoxify these products [5]. How-
ever, if detoxification is inefficient or absent within the
mother or the child due to genetic polymorphisms, the ex-
posed child may have a decreased ability to remove react-
ive oxygen species properly. Furthermore, effects of
prenatal and early childhood exposure to tobacco smoke
may persist through time, thus leading to reduced lung
function growth even in adolescence. Additional exposures
during adolescence, such as personal smoking, may further
affect the growth trajectory in lung function in vulnerable
individuals as well; therefore, it is important to control for
these factors as well in order to determine the pure joint
effects of tobacco smoke exposures and genetic polymor-
phisms responsible for detoxification.
The glutathione S-transferases (GST) are a superfamily
of catalytic proteins responsible for detoxification of
xenobiotic compounds, in conjugation with glutathione.
There are seven classes of the GST superfamily: alpha,
mu, pi, sigma, theta, omega, and zeta [5]. While the ef-
fects of glutathione S-transferase mu 1 (GSTM1) dele-
tion have been extensively studied, results of studies
examining these effects on various pulmonary outcomes
are in conflict [6-11]. For instance, findings in a study
among German schoolchildren aged 9 to 11 years only
found a significant interaction between GSTM1 status
and in utero smoke exposure on maximum mid expira-
tory flow (MMEF) levels [10], however Henderson et al.
while confirming a detrimental effect of intrauterine to-
bacco smoke exposure on childhood lung function
found no strong evidence of modification by maternal or
child GSTM1 genotype [12]. Regarding growth, only one
study found an association between GSTM1 gene func-
tion and lung function growth, where children with the
GSTM1 deletion had slower lung function growth com-
pared to those with the normal genotype [6]. In addition
to copy number variation of the GSTM1gene, genetic
variation in the form of single nucleotide polymorphisms
(SNPs) within other members of the GST family also
needs to be considered as it may lead to reduced expres-
sion of enzymes that detoxify harmful products that im-
pact lung function growth.
One explanation for conflicting results of studies of
the GSTM1 deletion is the failure to consider the impactof SNP variation in the adjacent GSTM2-5 loci. This is
highlighted by the study of Breton et al. where GSTM2
was associated with growth in FEV1 and MMEF; GSTM4
was associated with FEV1, FVC, and MMEF; GSTM3
and GSTM5 were associated with MMEF; and in utero
smoke exposure modified the effect of GSTM2 haplo-
types on growth in FEV1 and FVC [13]. Because of these
independent effects of variation within the GSTM2-5
loci on lung health, it is important to take this into ac-
count when examining the effect of GSTM1 variation on
lung function growth in adolescence.
An alternative explanation for variation between stud-
ies in genetic epidemiology is variation in environmental
exposure between cohorts [14]. Effects of genetic poly-
morphisms may be only seen in exposed populations, or
vice versa, and in some circumstances, ‘flip-flop’ effects
may be present where the effect of alleles on disease out-
come is reversed depending on environmental exposure.
Environmental exposure may also result in epigenetic ef-
fects such as altered DNA methylation that may either
mask or synergize with the effects of germline genetic
variation on phenotype [15]. For example in utero to-
bacco smoke exposure has been shown to result in
changes in DNA methylation in cord blood DNA [16]
that persist until adulthood (unpublished observations).
Thus far, only one study has reported the effects of
genetic variation found in GSTM2-5 and their inter-
action effect with tobacco smoke exposure on lung func-
tion levels and growth in late adolescence, where in
utero smoke exposure modified the effect of GSTM2 on
lung function growth [13]. Since active smoking only
had marginally significant effects on FEV1 and FEV1/
FVC at age 18 in the Isle of Wight (IOW) cohort (un-
published observations), the effect may only be detected
in those with a genetic susceptibility, acting through an
epigenetic mechanism. To expand these findings, we an-
alyzed data collected in the IOW birth cohort study.
Specifically, we explore the interactive relationships be-
tween smoking status and individual GSTM diplotypes.
Furthermore, we validated whether or not smoke expo-
sures modified the effect of diplotypes on methylation
levels of CpG sites within this gene cluster and deter-
mined whether or not methylation levels of these CpG
sites affected lung function levels at age 18.
Methods
Study population
From January 1989 to February 1990 in the IOW, UK,
1,536 children were born; 1,456 mother-child pairs were
enrolled into the cohort study. The local research ethics
committee (National Research Ethics Service, NRES Com-
mittee South Central–Southampton B) approved the study
and informed written parental consent was obtained for
all participants at recruitment and subsequently at each
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detail elsewhere [17-19].
Lung function measurement
At ages 10 and 18 years, pulmonary function tests,
which included forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), and FEV1/FVC ratio,
were performed on all consenting children (n=1,121).
Because mixed models can handle unbalanced data sets,
characteristics of the analytic sample (children with pul-
monary function test data available at age 10, age 18, or
both) were compared with characteristics of the total co-
hort. Details of lung function measurement performed
at ages 10 and 18 years were reported elsewhere [19].
Briefly, lung function measurements were conducted
using a Koko Spirometer and software with a desktop
portable device (PDS Instrumentation, Louisville, USA),
according to American Thoracic Society guidelines [20].
Children were required to be free from respiratory infec-
tion for 14 days and were not taking oral steroids. In
addition, they abstained from any β agonist medication
for six hours and caffeine intake for at least four hours.
Laboratory analysis
Details on genomic DNA extraction from whole blood
samples collected at age 18 and genotyping can be found in
the online supplement (Additional file 1). Genomic DNA
obtained from a subsample of female subjects (N=245)
were bisulfite-converted and applied to the Infinium
HumanMethylation450 BeadChip from Illumina (Illumina,
San Diego, CA, USA), which is used to assess methylation
in over 484,000 CpG sites found within approximately
24,000 genes. Arrays were processed using a standard
protocol as described elsewhere [21], with multiple identi-
cal control samples assigned to each bisulphite conver-
sion batch to assess assay variability and samples
randomly distributed on microarrays to control against
batch effects. The BeadChips were scanned using a
BeadStation, and the methylation level (beta value) cal-
culated for each queried CpG locus using the Methyla-
tion Module of BeadStudio software. All GSTM2-5
SNPs of interest were checked against a database
containing SNPs that may artificially alter GSTM2-5
CpG site methylation produced from dbSNP build v130
[22]. Also, CpG sites were excluded from further ana-
lyses if nearby probe SNPs affected their methylation.
Covariates
Smoking during pregnancy was ascertained at enroll-
ment, soon after the birth of the child. Information on
tobacco smoking by mothers, by fathers or any other in-
dividual within the household was recorded at recruit-
ment and updated at each follow-up at ages 1, 2, 4, 10,
and 18 to assess secondhand smoke (SHS) exposure forages 10 and 18 years. Personal smoking status of the
offspring was collected via questionnaires and validated
through urinary cotinine levels (ng/mmol) at age 18.
Height in centimeters (cm) and weight in kilograms
(kg) were assessed by study investigators at ages 1, 2, 4,
10, and 18 years; body mass index (BMI) was calcu-
lated. To ensure that effects of GSTM2-5 loci were in-
dependent of GSTM1, rs366631, a pseudo-SNP that
acts as a GSTM1 deletion marker, was included as one
of the covariates [23].
Statistical analysis
Haploview 4.2 [24] was used to assess each SNP for
Hardy-Weinberg equilibrium (HWE) and create linkage
disequilibrium (LD) blocks using the Gabriel et al.
method.[25] SNPs with a HWE p-value ≥ 0.01 and with
a minor allele frequency (MAF) ≥ 5% were considered
for diplotype formation. Haplotypes were generated in
Phase 2.1 [26,27] and were linked as pairs if the prob-
ability of constituting a pair was >0.60. The advantage
of using diplotypes is that each study subject has only
one diplotype. Usage of haplotypes would double the
sample size, thereby deflating variance and p-values
[28]. Diplotypes with frequencies of 5% or less were
combined into a “minor pairs” category. Diplotypes
were characterized according to the sequence of the al-
leles involved (e.g. TC_TC or both haplotypes having
thymidine and cytosine).
Statistical analyses were conducted using SAS 9.2
(Cary, NC) to assess effect of SNPs and diplotypes on
lung function growth. Linear mixed models were ap-
plied to adjust for correlations between the repeated
measurements. Models were built with an unstructured
covariance matrix, which requires the least amount of
constraints. Other covariance matrices were applied,
but no other covariance matrix improved the fit
(Akaike information criteria and Bayesian Schwarz in-
formation criterion).
Separate models for changes of FEV1, FVC, and FEV1/
FVC over time were created. Significance of interactions
(α = 0.05) was assessed first, then confounders were re-
moved if they did not change the estimates of diplotype
categories by at least 10%. The most frequent diplotype
served as the reference group, allowing us to assess the
effects of less common pairs on lung function outcomes.
Due to the number of hypothesis tests being conducted,
diplotypes were declared significant at a false discovery
rate (FDR) of 0.05 within each lung function outcome.
The overall effect of the diplotype blocks were evaluated
through the global F-test. To determine joint effects of
diplotypes and smoke exposures, separate models were
constructed for each type of diplotype-smoking inter-
action and were examined for significance through the
global F-test. Part A of Figure 1 provides an overview of
Part A – Main effects of genetic variation and  
interaction with smoke exposure
Part B – Main effects of epigenetic variation and  
interaction with genetic variation
Step 1: Are GSTM2-5 diplotypes influencing 
methylation of CpG sites in GSTM2-5 cluster? 
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Reject CpG site
Step 2 : Are methylation levels in GSTM2-5




Step 3 : Are methylation levels in GSTM2-5 
CpG sites associated with lung function at age 
18?
YES Step 4: Are GSTM2-5CpG
site methylation levels 
modifying the effect of 
GSTM2-5 diplotypes on 





Step 1: Are GSTM2-5 diplotypes 
influencing lung function growth 
during adolescence?
Step 2 : Are GSTM2-5 SNPs 
influencing lung function growth 
during adolescence?
Step 3 : Are smoke exposures 
modifying the effect of GSTM2-5
diplotypes on lung function growth 
during adolescence?
Figure 1 Overview of data analysis plan. Part A describes analysis plan to assess main genetic effects of GSTM2-5 diplotypes and single
nucleotide polymorphisms (SNPs) and their interactions with smoke exposures. Part B outlines the CpG site screening process and the plan to
find methylation quantitative trait loci (methQTL), conditioned on smoking, and the joint effect of modifiable genetic variants (modGVs) and DNA
methylation on lung function.
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maternal and active smoking, we compared cotinine
levels of individuals belonging to exposed and unex-
posed groups using the Wilcoxon-Mann–Whitney test.
Individuals who did not actively smoke were examined
to assess the pure effect of SHS exposure.
Methylation quantitative trait loci (methQTL) analyses
were performed via Wilcoxon-Mann–Whitney tests to
select CpG sites housed in the GSTM2-5 cluster that
varied by diplotype among a subset of participants with
methylation information (n=245). Because tobacco
smoke exposure is postulated to interact with certain
diplotypes and produce epigenetic changes, general lin-
ear models were used to assess the joint effect of
diplotypes and tobacco smoke exposure on methylation
levels of GSTM2-5 CpG sites. GSTM2-5 CpG sites that
were the result of a significant interaction were then
tested whether they modified the effect of diplotypes
(modifiable genetic variants [modGV]) [15] on lung
function levels at age 18 using general linear models,
adjusting for confounders. Joint effects of these CpG
sites and other GSTM2-5 modGVs were also examined.
Part B of Figure 1 gives an overview of this analysis plan.
Findings were verified through path analytical models.
More details on path analysis are found in the supple-
ment (Additional file 1).Results
Data on lung function measures were available for 1,121
children (Table 1). No significant differences were found
between this subsample and the total cohort (n = 1,456).
All SNPs in the GSTM2-5 loci were in HWE and had a
MAF ≥ 5% (Table 2). SNPs within each gene formed
their own blocks based on linkage disequilibrium (LD)
measures, where the r2 value was 0.8 or greater. A total
of four blocks were generated (Additional file 1: Figure
S2). The each block was comprised of the following
SNPs: GSTM2 rs574344 and rs12024479; GSTM3
rs1537236, rs7483, and rs7537234; GSTM4 rs668413,
rs560018, and rs506008; and GSTM5 rs929166 and
rs11807; (Additional file 1: Table S1). All reported p-
values were adjusted for multiple testing for an FDR of
0.05, when applicable. Only GSTM3 and GSTM5 show
direct associations with gain in FEV1 or FVC (Table 3).
Statistical analyses of the individual effects of SNPs
within the GSTM2-5 cluster on gain in each lung func-
tion outcome yielded no significant findings (Additional
file 2: Table S2). When looking at main effects of
GSTM2-5 diplotypes by age, only GSTM5 diplotypes
contributed to FEV1 levels at age 10 (Additional file 3:
Table S3a). Several interactions between GSTM2-5
diplotypes and smoke exposures were detected, but only
at age 18. SHS modified the relationship between
Table 1 Characteristics of subsample with lung function measurements and the total Isle of Wight (IOW) cohort
Subsample with lung function measurements (n=1121) Total cohort (n=1536)
Variables N % N % p-value
Gender
Males 557 49.7 786 51.2 0.45
Females 564 50.3 750 48.8
Missing 0 0
In utero smoke exposure
Yes 253 22.7 384 25.2 0.12
No 864 77.4 1137 74.8
Missing 419 15
SHS smoke exposure at age 10
Yes 508 45.3 848 56.7 0.26
No 609 54.3 647 43.3
Missing 419 41
SHS smoke exposure at age 18
Yes 563 55.2 716 56.7 0.49
No 457 44.8 548 43.3
Missing 516 272
Active smoking at age 18
Yes 276 26.9 368 28.8 0.30
No 752 73.2 910 71.2
Missing 508 258
Median (5th percentile, 95th percentile); n
Height at age 10 (cm) 138.7 (129.1, 149.5); 1026 138.7 (129.1, 149.5); 1043 0.98
Missing 510 493
Height at age 18 (cm) 171.0 (156.5, 186.5); 918 171.0 (156.5, 187.0); 994 0.64
Missing 618 542
BMI at age 10 (kg/m2) 17.4 (14.7, 24.1); 1026 17.4 (14.7, 23.9); 1043 0.92
Missing 510 493
BMI at age 18 (kg/m2) 22.2 (18.2, 32.2); 896 22.2 (18.2, 32.2); 964 0.91
Missing 640 572
SHS Secondhand smoke, BMI Body Mass Index.
Alexander et al. BMC Pulmonary Medicine 2013, 13:56 Page 5 of 11
http://www.biomedcentral.com/1471-2466/13/56GSTM2 and FEV1 and FVC levels (pinteraction = 0.004
and pinteraction = 0.0003, respectively) (Additional file 3:
Table S4b); SHS modified the relationship between
GSTM3 and FEV1 levels (pinteraction = 0.04) (Additional
file 3: Additional file 3: Table S5b; and active smoking
modified the relationship between GSTM5 and FEV1
and FVC levels (pinteraction = 0.004 and pinteraction = 0.05,
respectively) (Additional file 3: Table S7c).
Multivariable analyses
GSTM2
Diplotypes within the GSTM2 locus did not signifi-
cantly contribute to gain in FEV1, FVC, and change in
FEV1/FVC ratio (Table 3). Additionally, no statisticallysignificant interactions between diplotypes and to-
bacco smoke exposures were detected (Additional file
3: Tables S8a-c).
GSTM3
The overall effect of variations in diplotypes within
GSTM3 neared significance for gain in both FEV1
and FVC (p = 0.12 and p = 0.08, respectively). After ad-
justment for false discovery rate, one diplotype was asso-
ciated with significantly lower gain in FEV1 (GGG_GGG:
-63.81 mL, p = 0.03) (Table 3). This diplotype also pro-
duced detrimental effects on gain in FVC, but it was not
significant (GGG_GGG: -51.91, p = 0.09). An additional
diplotype was associated with significantly lower gain in
Table 2 Genotype information of GSTM2-5 single nucleotide polymorphisms
Gene SNP Base pair position Location Genotype Genotype frequency (%) Minor allele frequency (MAF) (%)
GSTM2 rs574344 110015037 Intron AA 0.5 7.6
AT 14.2
TT 85.3
rs12024479 110021609 Flanking 3’-UTR* CC 27.2 48.1
CG 49.4
GG 23.4
GSTM3 rs1537236 110080495 3’-UTR* AA 23.4 49.3
AG 51.8
GG 24.8
rs7483 110081224 Exon AA 9.3 29.7
AG 40.8
GG 50.0
rs10735234 110083464 Intron AA 32.3 34.5
AG 49.0
GG 18.7
GSTM4 rs668413 109997467 Flanking 3’-UTR* AA 17.3 41.0
AC 47.4
CC 35.3
rs560018 110001883 Intron AA 42.7 34.7
AG 45.3
GG 12.1
rs506008 110003222 Exon AA 2.1 14.2
AG 24.2
GG 73.7
GSTM5 rs929166 110056697 Intron AA 55.2 26.7
AC 36.2
CC 8.6
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bacco smoke interactions, SHS exposure marginally
modified the relationship between GSTM3 diplotypes
and change in FEV1/FVC (pinteraction = 0.06) (Additional
file 3: Table S9b). Statistically significant interactions be-
tween diplotypes within GSTM3 and in utero smoke ex-
posure and personal smoking at age 18 were not
observed (Additional file 3: Tables S9a and S9c).
GSTM4
Overall, diplotypes created in the GSTM4 locus had
no significant effects on gain in FEV1, FVC, and
change in FEV1/FVC ratio (Table 3). Additionally, no
significant interactions with in utero smoke exposure,SHS exposure, and personal smoking at age 18 were
observed (Additional file 3: Tables S10a-c).
GSTM5
Global F-tests indicated a significant contribution of
GSTM5 diplotypes to gain in FEV1 (p = 0.02, Table 3).
Only one pair showed a statistically significant positive
relationship with gain in FEV1 (AA_CA: 53.26 mL,
p = 0.04). Although the interaction between GSTM5
diplotypes and SHS exposure appeared to affect FEV1/
FVC change, this relationship was not statistically sig-
nificant (p = 0.08) (Additional file 3: Table S11b). No
other statistically significant interactions were seen
between this diplotype group and in utero smoke
Table 3 Adjusted linear mixed models examining the main effects of diplotypes within GSTM2-5 cluster on repeated
lung function measurements from ages 10 to 18 years
Forced expiratory volume in 1 second (FEV1) Forced Vital Capacity (FVC) FEV1/FVC
Gene N Diplotype* β (mL) p-value§ β (mL) p-value§ β (%) p-value§
GSTM2 1020 TC_AC −5.93 0.97 −24.16 0.80 0.69 0.76
TC_TC −25.11 0.97 −37.94 0.34 0.14 0.77
TG_AC −6.09 0.97 −16.20 0.80 0.38 0.76
TG_TG 8.69 0.97 −5.15 0.80 0.50 0.76
Minor diplotypes 5.27 0.97 −40.58 0.80 2.18 0.76
TC_TG REF – REF – REF –
p-value‡ 0.78 0.59 0.85
GSTM3 1037 AAA_AAA −47.38 0.11 −50.5538 0.11 0.62 0.73
AGA_AAA −56.42 0.09 −83.1151 0.02 0.74 0. 73
AGA_GGG −38.32 0.11 −34.2516 0.15 0.26 0.79
GGA_GGG −41.55 0.23 −60.1746 0.11 0.81 0. 73
GGG_GGG −63.81 0.03 −51.9142 0.09 −0.15 0.79
Minor diplotypes −53.28 0.09 −54.6330 0.09 −0.17 0.79
AAA_GGG REF – REF – REF –
p-value‡ 0.12 0.08 0.72
GSTM4 1028 AGG_AGG −0.37 0.99 28.10 0.42 −0.53 0.60
CAA_AGG 24.05 0.98 34.38 0.42 −0.10 0.88
CAG_AAG −13.55 0.98 −23.75 0.57 0.38 0.79
CAG_CAA 15.47 0.98 37.69 0.42 −0.51 0.60
CAG_CAG −8.92 0.98 12.74 0.57 −0.67 0.60
Minor diplotypes 6.55 0.98 35.15 0.42 −0.94 0.60
CAG_AGG REF – REF – REF –
p-value‡ 0.91 0.54 0.69
GSTM5 1002 AA_AG 23.81 0.48 6.13 0.89 0.48 0.67
AA_CA 53.26 0.04 31.88 0.50 0.60 0.67
AG_CA −24.22 0.48 −30.40 0.50 −0.42 0.67
CA_CA −6.40 0.83 4.47 0.89 −0.47 0.67
Minor diplotypes −41.33 0.48 −51.04 0.50 −0.27 0.78
AA_AA REF – REF – REF –
p-value‡ 0.02 0.24 0.45
Note: Bold indicates statistically significant difference in lung function compared to referent group (p ≤ 0.05);
* Comprised of SNPs as described in the Results section; †Models adjusted for sex, rs366631, in utero smoke exposure, current smoking, secondhand smoke
exposure, and body mass index (BMI); ‡ Global F-test p-value: combined effect of diplotypes on repeated lung function measurements; § After adjustment for
false discovery rate (FDR).
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Tables S11a and S11c).
Methylation analyses
Although no effects of significant interactions on lung
function growth were present in this study, the GSTM2×in
utero smoke exposure interaction was found to be signifi-
cant in Breton et al. [13], suggesting that this smoke
exposure changed the function of this gene through epi-
genetic modifications. As a result, methylation levels in
this gene cluster were investigated for their role in lungfunction. After removal of 25 CpG sites that may be af-
fected by probe SNPs, methQTL analyses revealed that
several CpG site methylation levels were dependent on
genetic variants of the specific gene: diplotypes of the
GSTM2 diplotypes predicted three CpG site methylation
levels; GSTM3 diplotypes predicted five CpG site methyla-
tion levels; GSTM4 gene predicted five CpG site methyla-
tion levels; and GSTM5 diplotypes predicted one CpG site
methylation levels (Additional file 3: Table S12).
When looking at the joint effect of GSTM2-5 diplotypes
and tobacco smoke exposures (SHS and active smoking),
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ship between GSTM2 diplotypes and one CpG site found
in GSTM2: cg06970744 (pinteraction = 0.01; Table 4). How-
ever, these sites did not predict lung function levels at age
18 (Additional file 3: Table S13). The joint effect of this
CpG site and other modGVs had a significant relationship
with FEV1 (cg06970744× GSTM5: pinteraction = 0.02) and
FVC levels at age 18 (cg06970744× GSTM5: pinteraction =
0.02) (Table 5). Increasing levels of methylation at
cg06970744 produced increased FEV1 and FVC levels for
individuals with the CA_CA diplotype in GSTM5.
Results of the path analyses revealed no indirect effects
of diplotypes on lung function through methylation at
cg06970744 at age 18 (Additional file 3: Table S14).
Discussion
Results suggest that variation within the GSTM3 and
GSTM5 loci had significant impact on lung function out-
comes at age 18 after adjustment for confounding. Some
diplotypes, but none of their interactions with smoke ex-
posure (in utero, SHS, or active smoking exposure at
18), produced an independent, statistically significant re-
lationship with FEV1 and FVC, but not with FEV1/FVC.
Additional analyses suggest a multi-stage model. First,
DNA methylation was affected by diplotypes condition-
ally on smoking exposure; second, an altered DNA
methylation modified the effect of diplotypes on lung
function (acting as modGVs), leading to significant ef-
fects of GSTM2 and GSTM5 on FEV1 and FVC. Path
analyses show that methylation at cg06970744 did not
lie on the pathway between GSTM5 diplotypes and lung
function, further providing evidence that methylation at
certain sites can modify the effect of genetic variation on
an outcome. Also, methylation at this site appears to be
unaffected by nearby SNPs (unpublished observations).
Several GSTM3 diplotypes had strong, negative effects
on gain in lung function. SNPs in GSTM3 included aTable 4 Adjusted estimates of GSTM2 diplotypes on GSTM2 C
status at age 18
cg03942855†
Not exposed (n = 93) Exposed (n = 1
Diplotype* β (%) p-value§ β (%) p-v
TC_AC −2.09 0.31 −1.61 0
TC_TC 1.62 0.31 −1.80 0
TG_AC −1.92 0.33 −4.12 0
TG_TG −1.99 0.31 −1.99 0
Minor diplotypes −3.88 0.33 2.26 0
TC_TG REF – REF
pinteraction‡ 0.03
* Comprised of SNPs as described in the Results section; †Models adjusted for in ut
significance of interaction; § After adjustment for false discovery rate (FDR).functional SNP (rs7483). Previous studies have found an
association with this SNP and Alzheimer’s disease [29,30].
Breton et al. have previously examined the association of
rs7483 with lung function, and similar to the present
study, no significant associations were found [13]. GSTM4
had a synonymous coding SNP (rs506008). This SNP
produced positive, but insignificant effects on lung func-
tion across time and thus more than likely does not make
contributions to lung function at the diplotype level. There
are no reported associations between rs506008 and any
disease outcomes. Although GSTM5 had no functional
SNPs, there was a significant lung function improve-
ment in those who possessed the AA_CA diplotype,
demonstrating a need to investigate this particular re-
gion. Only one of the SNPs (rs11807) was previously
reported in the literature, showing a strong association
with hypertension [31]; however, no association with
lung function had been reported.
Due to previous findings that showed lower lung func-
tion outcomes due to various tobacco smoke exposures
[2-4,32], we assessed the critical period where lung de-
velopment may be severely impaired by tobacco smoke
exposure. No two-way interaction effects of tobacco
smoke with GSTM2-5 loci were seen, which is in con-
trast to findings by Breton et al., who reported inter-
action effects with GSTM2 and in utero tobacco smoke
[13]. This discrepancy may be either due to misclassifi-
cation of the exposure and/or insufficient sample size in
our study or missing replication in the study by Breton
et al. [13]. Because questions involving tobacco smoke
exposure at age 18 were validated with urinary cotinine
levels (Additional file 3: Table S9), there is no suggestion
of major misclassification, as those who were active
smokers or were exposed to SHS had significantly higher
levels of cotinine compared to nonsmokers. The study
by Breton et al. included at least one more repeated
measurement [13], hence, it is possible that the presentpG site methylation by secondhand smoke exposure
cg06970744†
30) Not exposed (n = 93) Exposed (n = 130)
alue§ β (%) p-value§ β (%) p-value§
.33 −0.53 0.80 −2.16 0.34
.03 2.19 0.42 −2.75 0.02
.002 2.64 0.51 −3.14 0.07
.02 −2.38 0.42 −3.28 0.01
.50 −4.04 0.57 3.23 0.48
– REF – REF –
0.01
ero smoke exposure and personal smoking status; ‡ Global F-test p-value:
Table 5 Adjusted means of FEV1 and FVC in mL by diplotype and CpG methylation percentile
Methylation percentile for cg06970744†,§
Outcome Gene n Diplotype* 25th percentile 50th percentile 75th percentile pinteraction ‡
FEV1 GSTM5 203 AA_AG 3427.61 3457.13 3497.90 0.02
AA_CA 3584.62 3549.29 3500.49
AG_CA 3584.46 3536.99 3471.43
CA_CA 3206.02 3349.07 3546.64
Minor diplotypes 3527.80 3721.73 3989.59
AA_AA 3499.59 3503.89 3509.84
FVC GSTM5 203 AA_AG 4020.50 4036.67 4059.00 0.02
AA_CA 4091.55 4067.27 4033.75
AG_CA 3864.29 3951.14 4071.09
CA_CA 3850.02 4016.73 4246.98
Minor diplotypes 4004.33 4292.32 4690.09
AA_AA 3975.89 3981.64 3989.57
*Comprised of SNPs as described in the Results section, means for minor diplotypes grouping in GSTM2 were not estimable; †Models adjusted for rs366631, in
utero smoke exposure, current smoking, secondhand smoke exposure, body mass index (BMI) and height; ‡ Global F-test p-value: significance of interaction; §
Name of methylation site is derived from Illumina ID.
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teractions. However, there is a need of replication studies
to examine the role of these genes on lung function in
conjunction with tobacco smoke exposure, especially in
different environments. It is also necessary to consider
that other environmental and lifestyle exposures includ-
ing air pollution and paracetamol (acetaminophen) use
[33] may also alter oxidative stress [34] and mask or
falsely indicate an effect of related exposures. Air pollu-
tion was not controlled in the study by Breton et al.
[13], but was reported to modify the effect of a similarly
functioning gene (GSS) on lung function growth in an-
other study of this group [33]. Because it has been sug-
gested in the literature that tobacco smoke exposure,
especially in utero [35], may epigenetically modify these
genes, hence changing the function of these genes, we
tested the effect of CpG sites on lung function levels at
age 18. Although there were no independent effects of
these CpG site methylation levels on lung function out-
comes, it is interesting to note that these effects were
not seen until joint effects of GSTM2 and GSTM5
diplotypes were taken into account, indicating that DNA
methylation may modify the effect of genetic variants on
lung function, a mechanism that needs further investiga-
tion [15]. These findings may also help explain the lack
of consistency between the present study’s findings and
the findings of Breton et al. [13]. It may not be the geno-
type that produces inconsistent results, but rather differ-
ent DNA methylation levels in different study groups
that accounted for the discrepancy.
To further lend validity to this study, selection bias was
not apparent regarding availability of lung function data.
Approximately 95% (1456/1536) of mother-child pairswere enrolled into this study; and those who underwent
pulmonary function tests were not significantly different
from the total cohort (Table 1). Also, lung function
measurements were obtained under standardized con-
ditions in a prospective manner, decreasing the likeli-
hood of information bias. With respect to genotyping
data, all SNPs that were shared with Breton et al. were
in HWE and had comparable frequencies with Cauca-
sians in their sample [13]. These polymorphisms also
agreed substantially in their association with FEV1 and
FVC with our findings (Additional file 1: Figure S2 and
Additional file 2: Figure S3). In regard to haplotypes,
diplotypes (haplotype-pairs) were used, thus reducing
uncertainty and subsequently misclassification of individ-
uals, which is often encountered in haplotype association
studies [36]. Also, our population was homogeneous,
meaning controlling for population stratification is un-
necessary and ensures HWE, which appeared to be an
issue for Breton et al. [13], possibly resulting in different
findings. While SNPs included in the haplotype analysis
of the latter study were in HWE within ethnic groups,
they were not in HWE when examining the entire
population [13]. This is problematic because inclusion
of SNPs that deviate from HWE may produce spurious
associations between haplotypes and lung function
[37,38]. In addition, the findings by Breton et al. [13]
may be due to population stratification. The authors
identified ancestry indicators, controlled these as con-
founders but did not stratify their analysis by these
markers. Nevertheless, population stratification ad-
dresses the possibility that haplotypes may reveal differ-
ent associations in different ethnic/racial strata. This
may also account for the lack of agreement of single
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present study and the Breton et al. study [13].
Despite the strengths of our study, some limitations
are present. First, because maternal smoking and active
smoking during adolescence is obtained via self-reported
questionnaires, misclassification of this exposure is pos-
sible. Our previous publications have shown that mater-
nal smoking during pregnancy interacts with the IL13
and IL1RN genes and increases the risk of asthma and
wheezing [39,40]. Hence, ascertainment of maternal
smoking seemed to provide valid information. However,
maternal smoking × IL13 and IL1RN gene interaction
assumes an effect of smoking on these genes. Against
that, GSTM2-5 × maternal smoking interactions assume
that the genes regulate the toxicity of tobacco smoke,
possibly via epigenetic mechanisms. Also, based on re-
sults of the methylation analyses in the present study,
the joint effect of maternal smoking and GSTM2-5
diplotypes did not influence methylation levels of CpG
sites within the GSTM2-5 cluster; however, these methy-
lation levels were captured at age 18 and therefore we
cannot ascertain whether or not epigenetic changes had
taken place due to this particular exposure nor can we
determine that methylation levels at age 18 are represen-
tative of early-life methylation profiles. Regarding valid-
ation of other smoke exposures, passive smoke exposure
and active smoking at age 18 was associated with in-
creased cotinine levels. Also, active smoking at age 18
led to deficits in FEV1/FVC after adjustments for
GSTM5 diplotype, GSTM1 genotype, sex, BMI, height,
in utero smoke exposure, and SHS (Additional file 3:
Table S16). Reduced FEV1/FVC has previously been ob-
served in adolescent smokers [41].
Second, not all SNPs used in the Breton et al. study were
genotyped in this work. Therefore combinations of SNPs
that were not included in the haplotype construction may
lead to different results. Variation in FEV1 in these results
may be due to differences in population characteristics be-
tween the two studies, residual confounding, or as demon-
strated by methylation levels, differences in expression
levels of detoxification enzymes produced by this set of
genes. Based on the results of this study, methylation levels
at age 18 within this gene cluster can be ruled out because
analyses revealed no significant effect of methylation on
lung function levels at 18. The goal of this study was to ex-
pand upon findings by Breton et al. through accounting
for methylation [13].
Conclusions
Based on results of this study, it is clear that certain genes
within the GSTM2-5 loci explain some differences in lung
function in late adolescence; however, joint effects with to-
bacco smoke exposure were not detected. This finding was
validated through examination of joint effects of diplotypesand in utero smoke exposure, which did not significantly
alter methylation levels within this gene cluster. Only one
study has reported an interaction of maternal smoking with
GSTM2-5 genes [13]. A past genetic association study has
examined the interactive effects of maternal genotypes on
other GST genes [12], but no studies have examined the
joint effect of maternal genotype and GSTM2-5 genotypes
in their offspring. Future studies are necessary to elucidate
conflicting results, taking into account DNA methylation
×gene interactions, interaction with other xenobiotics af-
fecting the glutathione levels, and interaction with the ma-
ternal genome.
Additional files
Additional file 1: Sample collection, genotyping methods, and
haplotype blocks within GSTM2-5. This additional file contains
information on sample collection, genotyping, and haplotype block
creation (Figure S2) and diplotype frequencies (Table S1).
Additional file 2: Statistical analyses and results of SNP effects. This
additional file contains information on statistical methods used to analyze
effects of SNPs on lung function growth (Table S2). Two plots were
created to compare results from the present study with a study by
Breton et al. (Figures S3 and S4).
Additional file 3: Effect of GSTM2-5 diplotypes x smoke interactions
and CpG sites on lung function levels and lung function growth.
This file contains supplementary tables on main effects of GSTM2-5
diplotypes on lung function levels at ages 10 and 18 (Tables S3a and
S3b), interactions between GSTM2-5 diplotypes and smoke exposures on
lung function levels at ages 10 and 18 (Tables S4a-S4c, Tables S5a-S5c,
Tables S6a-S6c, and Tables S7a-S7c), interactions between GSTM2-5
diplotypes and smoke exposures on lung function growth (Tables S8a-
S8c, Tables S5a-S5c, and Tables S6a-S6c), the influence of diplotypes
on CpG site methylation (Table S12), the effect of CpG sites on lung
function growth (Table S13), validation of smoke exposure categories via
urinary cotinine (Table S15), and the effect of active smoking on lung
function levels at age 18 (Table S16).
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